17^th World Drug Delivery Summit

Biography

Biography: Sonakshi

Abstract

Alzheimer's Disease (AD), the most common form of dementia, gradually impairs an individual's memory and cognitive abilities. The disease slowly diminishes an individual's ability to carry out daily activities, affecting their behavior, personality, and language skills. Though Alzheimer's most commonly occurs in the later stages of life, it can impact people as early as their 40s. Alzheimer's is characterized by both beta-amyloid plaques and protein tangles composed of phosphorylated tau. Beta-amyloid plaques are caused by accumulations of the protein beta-amyloid, which can occur when the mechanisms that typically break down beta-amyloid protein malfunctions. P-Tau Protein tangles arise when the normal, healthy tau protein becomes phosphorylated, detaching from microtubules and aggregating into tangles that disrupt the normal functioning of nerve cells. As such a devastating disease, researchers have discovered treatments, such as investigational Drug XXX and Drug YYY (both remove amyloid plaques in the brain, preventing AD progression). Multiple ongoing trials are currently studying the effectiveness of the monoclonal antibody investigational drug ZZZ at removing the p-tau protein tangles in the brain, which has shown promising effects in slowing the cognitive and functional decline in patients diagnosed with AD. However, the prevention of AD has yet to be previously studied. Despite the groundbreaking discoveries in AD treatments, there is no way for the brain damage done by the protein plaques or tangles to be reversed: the patients' memories cannot be restored. This study aims to investigate whether the current drug –Drug ZZZ– used to clear out p-tau protein tangles in patients diagnosed with AD would be able to clear out p-tau protein in participants with preclinical AD. By effectively preventing any brain damage caused by the p-tau tangles, we could avoid or at least delay the onset of Alzheimer's Disease.